Following the SARS-CoV-2 genetic sequence made public by the Chinese Center for Disease Control and Prevention on January 10, 2020, BioNTech initiated the development of it’s COVID-19 vaccine mRNA sequence of which would become known as “BNT162b2”.
Following the SARS-CoV-2 genetic sequence made public by the Chinese Center for Disease Control and Prevention on January 10, 2020, BioNTech initiated the development of it’s COVID-19 vaccine mRNA sequence of which would become known as “BNT162b2”.